Astro Pak launches decontamination services subsidiary

Published: 26-Jan-2010
Hi Tech Manufacturing Finance Cleaning

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.

SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.

The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.

The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.

Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.

In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
  • Companies:
  • Instant Cleanroom Solutions
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Finance

Oncoinvent patent win and CellCarta deal highlight IP power in oncology innovation

Read more
New patent protection for Radspherin and a global exclusivity deal for Aspyre Lung underline how strong IP strategies are driving competitive advantage in cancer therapeutics and diagnostics

Trending Articles

  1. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  2. Applied Biopharm Consulting secures IP grant to protect AI-driven viral capsid engineering innovations Irish biotech consultancy Applied Biopharm Consulting has received an IP Start Grant from Enterprise Ireland to develop a formal patent strategy around its AI-powered computational platform for engineered adeno-associated virus vector design
  3. CordenPharma Colorado expands peptide development capacity with lease of new lab Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    kyron.bio partners with Servier to advance precision glycosylation in antibody therapeutics The parternship will allow kyron.bio to apply its precision glycoengineering platform to antibody development. Speaking exclusively with Manufacturing Chemist, CEO of kyron.bio, Dr Emilia McLaughlin, explains the importance of the new deal
  5. Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Finance

Oncoinvent patent win and CellCarta deal highlight IP power in oncology innovation

New patent protection for Radspherin and a global exclusivity deal for Aspyre Lung underline how strong IP strategies are driving competitive advantage in cancer therapeutics and diagnostics
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Finance

TCI Biotech expands US manufacturing with $26m facility investment

Global biotechnology innovator TCI Biotech announces an investment of approximately $26.225m to expand its existing US manufacturing facility in American Fork, Utah
Finance

Applied Biopharm Consulting secures IP grant to protect AI-driven viral capsid engineering innovations

Irish biotech consultancy Applied Biopharm Consulting has received an IP Start Grant from Enterprise Ireland to develop a formal patent strategy around its AI-powered computational platform for engineered adeno-associated virus vector design
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Manufacturing

Lonza completes transformation to pure-play CDMO with agreement to divest Capsules & Health Ingredients

Sale of CHI business to Lone Star funds marks final step in Lonza’s strategic shift to a focused CDMO model
Subscribe now